Jupiter Neurosciences, Inc. (JUNS) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Jupiter Neurosciences, Inc. is a clinical-stage biopharmaceutical company developing JOTROL, a resveratrol-based therapeutic for neuro-inflammation and rare diseases (e.g., Parkinson's, Friedreich's ataxia). The company also operates a consumer segment, Nugevia, focused on premium nutritional supplements. The company is listed on the Nasdaq Capital Market and is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(2,252,965) | $(3,781,832) | $(320,977) |
| Operating Expenses | $2,264,880 | $3,802,883 | $1,127,772 |
| Cash and Equivalents (End of Period) | $1,878,247 | $1,878,247 | $14,851 |
| Operating Cash Flow | Not provided for Q2 | $(1,891,263) | $(172,627) |
| Accumulated Deficit | $(29,803,961) | $(29,803,961) | $(23,903,481) |
| Debt (Related Party Notes) | $146,432 | $146,432 | $146,432 |
Note: The company has no revenue from product sales to date. All convertible debt obligations were repaid or converted in December 2024.
Material Changes vs. Prior Period
- Expense Surge: Operating expenses increased significantly year-over-year. For the six months ended June 30, 2025, expenses were $3.8 million compared to $1.1 million in the prior year period.
- R&D: Increased to $1.23 million (YTD 2025) from $0.20 million (YTD 2024), driven by a new three-year service agreement for Southeast Asian market development and procurement of clinical trial supplies for the Parkinson's program.
- G&A: Increased to $2.58 million (YTD 2025) from $0.93 million (YTD 2024), attributed to full salary payments to employees (previously deferred), accrued bonuses, and increased legal/professional fees associated with Nasdaq listing compliance.
- Interest Expense: Decreased to $2,364 (YTD 2025) from $122,046 (YTD 2024) as all interest-bearing convertible notes were settled in late 2024.
- Derivative Liability: No loss on change in fair value of derivative liability in 2025, compared to a $63,142 loss in the prior year period, as the related notes were extinguished.
- Cash Position: Cash decreased by approximately $1.89 million during the six-month period due to operating losses, despite a strong cash balance at the start of the year following the December 2024 IPO.
Outlook, Risks, and Management Commentary
- Going Concern: Management states that historical losses, negative cash flows, and reliance on external financing raise substantial doubt about the company's ability to continue as a going concern for at least twelve months. Future operations depend on equity financing, grants, or strategic collaborations.
- Operational Milestones:
- Pharmaceutical: A Phase IIa clinical trial for Parkinson's disease is planned to start in Q4 2025, with results expected 12 months later.
- Consumer: The Nugevia product line (longevity supplements) is targeted for market launch in Q3 2025 via a Direct-to-Consumer model.
- Nasdaq Compliance: The company received notification in March 2025 regarding non-compliance with the $1.00 minimum bid price rule. It regained compliance in July 2025 after maintaining the price for 13 consecutive business days.
- Subsequent Events:
- July 2025: Board approved cash bonuses totaling $449,000 for officers, contingent on the company maintaining at least $3.5 million in cash on hand.
- July/August 2025: Several warrant exercises occurred, resulting in the issuance of approximately 943,846 shares of common stock.
- Risks: Key risks include the uncertainty of clinical trial outcomes, intense competition in the supplement and pharmaceutical markets, reliance on third-party manufacturers, and the need for additional capital to fund operations.
Investor Verification Checklist
- Liquidity Runway: Verify if the company can sustain operations with ~$1.9M cash given the ~$1.9M burn rate over six months, especially with the $449k bonus contingent on holding $3.5M cash.
- Revenue Timeline: Confirm the Q3 2025 launch date for Nugevia supplements and the Q4 2025 start date for the Parkinson's Phase IIa trial.
- Stock Dilution: Review the impact of recent warrant exercises and the 357,448 stock options granted in July 2025 on share count and EPS.
- Service Agreement Costs: Scrutinize the $2.3M prepaid contract with Dominant Treasure Health and the associated amortization expense impacting G&A.
- Accrued Compensation: Monitor the $1.86M accrued compensation liability and the company's ability to pay it without raising new capital.